The Chronic Kidney Disease (CKD) market in the United States was valued at approximately USD 2,824 million in 2023 and is expected to maintain steady growth over the forecast period. Among the 7MM, the US recorded the highest CKD prevalence, with an estimated 40 million cases in 2023, a number projected to rise by 2034. In terms of gender distribution, around 2 million males and 3 million females were affected in 2023. The current CKD treatment landscape – which includes erythropoiesis-stimulating agents (ESAs), ACE inhibitors, ARBs, diabetes management therapies, treatments for secondary hyperparathyroidism (SHPT), and urate-lowering agents – resulted in a total 7MM market size of USD 5,479 million in 2023. This market is expected to expand further with the introduction of new therapies through 2034.
A key development includes Boehringer Ingelheim’s BI-690517, a selective aldosterone synthase inhibitor, which demonstrated a 39.5% reduction in albuminuria over 14 weeks when combined with empagliflozin in a Phase II study – marking the first trial of its class alongside standard care. These results, showcased at ASN Kidney Week 2023, highlight the shifting treatment landscape for CKD.
Additionally, Japan’s CKD therapeutics market, valued at USD 1,402 million in 2023, is also expected to experience notable growth by 2034.
DelveInsight’s “Chronic Kidney Disease Market Insights, Epidemiology, and Forecast–2034” report offers an in-depth evaluation of CKD, covering past and future epidemiology and market dynamics across the US, EU5, and Japan. The CKD market is projected to grow significantly due to increasing disease prevalence and heightened awareness. Moreover, the anticipated introduction of several emerging therapies across different development stages is expected to transform the competitive landscape and future treatment approaches.
To know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast
Some of the key facts of the Chronic Kidney Disease Market Report:
Chronic Kidney Disease Overview
Chronic Kidney Disease (CKD) is a progressive condition characterized by the gradual loss of kidney function over time, impairing the body’s ability to filter waste, regulate fluids, and maintain electrolyte balance. It is commonly caused by diabetes, hypertension, and cardiovascular disorders, though genetic factors and autoimmune diseases also contribute. Chronic Kidney Disease often progresses silently, with symptoms emerging in advanced stages, such as fatigue, swelling, anemia, and metabolic complications. Diagnosis involves blood tests, urine tests, and imaging to assess kidney function and structural damage. Without timely intervention, Chronic Kidney Disease can advance to end-stage renal disease, requiring dialysis or kidney transplantation.
Get a Free sample for the Chronic Kidney Disease Market Report to know more about emerging therapies, fda approvals and growth factors @ Chronic Kidney Disease Treatment Market
Chronic Kidney Disease Epidemiology
DelveInsight’s assessment indicates that the total diagnosed prevalent population of Chronic Kidney Disease (CKD) across the 7MM reached approximately 16 million individuals in 2023. The United States reported the highest burden, with an estimated 5 million diagnosed cases, a figure projected to rise over the forecast period. Among the EU5, the United Kingdom exhibited the greatest prevalence (~2 million), followed by Germany (~1 million), while Italy recorded the lowest at 731,000 cases. Japan accounted for roughly 3 million diagnosed cases, representing about 22% of the 7MM total. In terms of disease severity, Stage 3 CKD constituted the largest segment in the US (~2.94 million cases in 2023). Furthermore, across the EU4 and the UK, females exhibited a marginally higher diagnosed prevalence than males, with 3.55 million female cases compared to 3.4 million male cases.
Chronic Kidney Disease Epidemiology Segmentation:
The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Patient Pool Forecast
Chronic Kidney Disease Market Outlook
The US Chronic Kidney Disease (CKD) therapeutics market reached approximately USD 2,824 million in 2023, accounting for the largest share (~52%) of the overall 7MM Chronic Kidney Disease market. Within Europe, the UK reported the highest Chronic Kidney Disease market value at USD 421 million, whereas Italy represented the smallest segment at roughly USD 132 million. Japan’s Chronic Kidney Disease therapeutics market was valued at USD 1,402 million in 2023 and is expected to grow steadily throughout the forecast period.
Chronic Kidney Disease treatment focuses on slowing disease progression, alleviating symptoms, and preventing complications. Core management includes lifestyle modifications – such as dietary adjustments, increased physical activity, and smoking cessation – with emphasis on limiting salt, potassium, and protein intake to minimize renal strain.
Pharmacologic interventions play a central role. ACE inhibitors and ARBs are widely used to manage hypertension and reduce proteinuria, thereby delaying disease progression. Statins help control dyslipidemia and lower cardiovascular risk, while glycemic management in diabetic CKD relies on therapies like metformin and SGLT2 inhibitors, which also offer renal protection. Anemia associated with CKD is treated using erythropoiesis-stimulating agents (ESAs) and iron supplementation.
In later disease stages, renal replacement therapies – including hemodialysis and peritoneal dialysis – become necessary. Kidney transplantation remains the optimal option for end-stage renal disease (ESRD), requiring ongoing immunosuppressive therapy. Comprehensive Chronic Kidney Disease management also involves controlling comorbid conditions such as hypertension, hyperglycemia, and lipid disorders, with continuous monitoring essential for improving clinical outcomes and quality of life.
Chronic Kidney Disease Therapies and Key Companies
To know more about Chronic Kidney Disease treatment, visit @ Chronic Kidney Disease Medications
Chronic Kidney Disease Market Drivers
1. Rising Disease Prevalence
Increasing CKD cases across the US, Europe, and Japan—driven by aging populations and higher rates of diabetes and hypertension—are significantly boosting market growth.
2. Advancements in Diagnostic Techniques
Improved screening tools, biomarkers, and routine renal function testing are enabling earlier detection, expanding the diagnosed patient pool.
3. Growing Adoption of Novel Therapeutics
Emerging drug classes such as SGLT2 inhibitors, non-steroidal MRAs, and aldosterone synthase inhibitors (e.g., BI-690517) are transforming treatment standards and fueling market expansion.
4. Increased Awareness and Clinical Guidelines
Greater physician and patient awareness, coupled with updated global CKD management guidelines, is driving higher diagnosis and treatment rates.
5. Strong R&D Pipeline
Robust clinical development efforts targeting renal protection, inflammation, and fibrosis are expected to introduce multiple innovative therapies by 2034.
Chronic Kidney Disease Market Barriers
1. Limited Treatment Options for Early Stages
Therapies primarily slow progression rather than reverse kidney damage, reflecting a major unmet medical need.
2. High Treatment Costs
Advanced therapies, dialysis, and transplantation are expensive, restricting market accessibility in some regions.
3. Adverse Effects of Long-Term Treatments
Long-term use of ACE inhibitors, ARBs, and ESAs can lead to safety concerns, limiting patient adherence.
4. Late Diagnosis
CKD often remains asymptomatic in early stages, resulting in delayed diagnosis and reduced therapeutic effectiveness.
5. Regulatory and Clinical Trial Challenges
Renal therapeutics require long, complex clinical trials and face stringent regulatory pathways, slowing product approvals.
Scope of the Chronic Kidney Disease Market Report
Discover more about therapies set to grab major Chronic Kidney Disease market share @ Chronic Kidney Disease Treatment Landscape
Table of Contents
1. Chronic Kidney Disease Market Report Introduction
2. Executive Summary for Chronic Kidney Disease
3. SWOT analysis of Chronic Kidney Disease
4. Chronic Kidney Disease Patient Share (%) Overview at a Glance
5. Chronic Kidney Disease Market Overview at a Glance
6. Chronic Kidney Disease Disease Background and Overview
7. Chronic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Kidney Disease
9. Chronic Kidney Disease Current Treatment and Medical Practices
10. Chronic Kidney Disease Unmet Needs
11. Chronic Kidney Disease Emerging Therapies
12. Chronic Kidney Disease Market Outlook
13. Country-Wise Chronic Kidney Disease Market Analysis (2020-2034)
14. Chronic Kidney Disease Market Access and Reimbursement of Therapies
15. Chronic Kidney Disease Market Drivers
16. Chronic Kidney Disease Market Barriers
17. Chronic Kidney Disease Appendix
18. Chronic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting/competitive-intelligence-services
